CPI-1189
CPI-1189 is an orally active TNF-α release inhibitor. CPI-1189 inhibits phosphorylation of p38. CPI-1189 can inhibit apoptosis. CPI-1189 can be used in the study of HIV and neurological diseases[1][2][3][4][5].
Product Specifications
CAS Number
183619-38-7
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; TNF Receptor
Type
Reference compound
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Infection; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/cpi-1189.html
Purity
99.82
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NC(C)(C)C)C1=CC=C(NC(C)=O)C=C1
Molecular Formula
C13H18N2O2
Molecular Weight
234.30
Precautions
H302, H315, H319, H335
References & Citations
[1]Müller T. CPI-1189. Centaur. Curr Opin Investig Drugs. 2002 Dec;3 (12) :1763-7. |[2]Clifford DB, et al. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology. 2002 Nov 26;59 (10) :1568-73.|[3]Li YJ, et al. CPI-1189 protects neuronal cells from oxygen glucose deprivation/re-oxygenation-induced oxidative injury and cell death. Aging (Albany NY) . 2021 Feb 17;13 (5) :6712-6723.|[4]Hensley K, et al. CPI-1189 inhibits interleukin 1beta-induced p38-mitogen-activated protein kinase phosphorylation: an explanation for its neuroprotective properties? Neurosci Lett. 2000 Mar 10;281 (2-3) :179-82.|[5]Bjugstad KB, et al. Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia. Brain Res. 1998 Jun 8;795 (1-2) :349-57.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
PKSQ050011-01 10 µg
Recombinant Cynomolgus LAG-3/CD223 Protein (His Tag)
Sign In for Pricing
View Details PKSQ050011-02 50 µg
Recombinant Cynomolgus LAG-3/CD223 Protein (His Tag)
Sign In for Pricing
View Details 
